1. Home
  2. BMHL vs TLSA Comparison

BMHL vs TLSA Comparison

Compare BMHL & TLSA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Bluemount Holdings Limited Class B Ordinary Shares

BMHL

Bluemount Holdings Limited Class B Ordinary Shares

N/A

Current Price

$3.22

Market Cap

152.9M

Sector

N/A

ML Signal

N/A

Logo Tiziana Life Sciences Ltd.

TLSA

Tiziana Life Sciences Ltd.

HOLD

Current Price

$1.08

Market Cap

145.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BMHL
TLSA
Founded
2016
2013
Country
Hong Kong
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
152.9M
145.1M
IPO Year
2024
2017

Fundamental Metrics

Financial Performance
Metric
BMHL
TLSA
Price
$3.22
$1.08
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
★ $8.02
AVG Volume (30 Days)
6.9K
★ 688.4K
Earning Date
03-30-2026
05-01-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$66.66
★ N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.72
$0.76
52 Week High
$6.35
$2.15

Technical Indicators

Market Signals
Indicator
BMHL
TLSA
Relative Strength Index (RSI) 27.95 51.86
Support Level $3.20 $0.90
Resistance Level $3.88 $1.20
Average True Range (ATR) 0.49 0.09
MACD -0.12 0.00
Stochastic Oscillator 8.75 43.59

Price Performance

Historical Comparison
BMHL
TLSA

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, is a Hong Kong-based consulting and advisory, financial services, and luxury timepiece trading provider. The Company provides consulting and advisory services on business development strategies, including seeking suitable transaction projects for business development or diversification and suitable business partners or investors for fund-raising projects. Its services are centered around three core offerings: Business Transformation, Strategy, and Transactions. The Company also sources, buys, and sells brand-new luxury branded timepieces. It operates through two reportable segments: security-related services and asset management, and trading of timepieces, with the trading of timepieces generating maximum revenue.

About TLSA Tiziana Life Sciences Ltd.

Tiziana Life Sciences Ltd is a clinical-stage biotechnology company that specializes in developing transformative therapies for neurodegenerative and neuroinflammatory diseases. The company's clinical pipeline includes drug assets for Non-Active Secondary Progressive Multiple Sclerosis, Multiple System Atrophy, Alzheimer's, and Amyotrophic Lateral Sclerosis. The company's mission is to design and deliver next-generation immunotherapies for neurodegenerative and neuroinflammatory diseases. The company's main immunotherapeutic candidate, Foralumab (TZLS-401), is being developed for Non-Active Secondary Progressive Multiple Sclerosis, Alzheimer's, and other CNS indications.

Share on Social Networks: